Invivyd (IVVD) Q3 2024 earnings summary

Executive summary

• Q3 2024 net product revenue for PEMGARDA reached $9.3 million, up from $2.3 million in Q2 2024, but was impacted by confusion over third-party virology data and FDA Fact Sheet updates, which were later corrected.

• CANOPY Phase 3 data showed 84% relative risk reduction for symptomatic COVID-19 at 6 months and 64% at 12 months off-drug in immunocompetent participants.

• PEMGARDA received FDA EUA in March 2024 for pre-exposure prophylaxis in immunocompromised individuals; EUA amendment for treatment submitted in July 2024.

• First-in-human clinical trial for next-gen antibody VYD2311 began dosing in August/September 2024, with preliminary data expected late Q4 2024.

• The company is focused on scaling access, awareness, and commercial optimization, with a mission to serve immunocompromised populations.

Financial highlights

• Q3 2024 net product revenue for PEMGARDA was $9.3 million; revenue for the nine months ended September 30, 2024, was $11.6 million.

• Cash and cash equivalents at September 30, 2024, totaled $106.9 million.

• Net loss for Q3 2024 was $60.7 million, up from $39.4 million in Q3 2023; net loss per share was $(0.51).

• R&D expenses rose to $57.9 million in Q3 2024, mainly due to VYD2311 development.

• Projected year-end 2024 cash and equivalents are at least $65 million, assuming continued revenue growth and efficiency gains.

Outlook and guidance

• Targeting near-term profitability in the first half of 2025, leveraging current cash, anticipated revenue growth, and operational efficiencies.

• Formal FY2024 revenue guidance was withdrawn due to FDA-related headwinds and market confusion.

• Management expects continued operating losses and negative cash flows without additional funding; substantial doubt exists about ability to continue as a going concern beyond one year.

• Guidance may be reinstated if revenue trends stabilize and confusion over product efficacy subsides.

• Multiple sources of additional capital are under evaluation.